glp-1 and parkinson's disease A new Science Perspective highlights the growing body of evidence that hints at the potential of GLP-1–based medications in treating conditions other than diabetes obesity, including cardiovascular and neurodegenerative disorders Schematic representation of the repurposing
Pay in 4 interest-free payments of $5.35 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Sep 2 - Sep 7



























